Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MS at the Limits 2022 | Progressive MS: discovering the new and repurposing the old

Emma Tallantyre, MD, PhD, Cardiff University, Cardiff, UK, discusses the recent research interest in seeking treatments for patients with established disability, as a consequence of advanced multiple sclerosis (MS). She explains that the use of screening platforms is allowing for existing compounds used to treat other diseases to be screened for potential benefits, such as remyelination or neuroprotection capabilities. This screening process has been useful in allowing compounds move through clinical development more quickly. Dr Tallantyre highlights that there are also new investigative medical compounds that are currently being studied in earlier phases of the disease. Beyond pharmacological interventions, focusing on brain health is also of great importance; for example, staying cognitively and physically active and making healthy lifestyle changes. Dr Tallantyre acknowledges the importance of taking a holistic approach to slow down the biological aging process and subsequently slowing the progression of MS. This interview took place during the 2022 Multiple Sclerosis at the Limits Conference in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

In the last 5 years, Dr Tallantyre has received honorarium for consulting work from Biogen, Janssen, Merck, Novartis, and Roche. She has received travel grants to attend or speak at educational meetings from Biogen, Merck, Roche, Takeda and Novartis.